February 18, 2026
Wei Wang, Ph.D., research associate professor, has joined a $3.2 million effort to develop a promising new treatment for triple-negative breast cancer (TNBC), one of the most aggressive and difficult-to-treat forms of the disease. The team is developing a new kind of drug designed to attack MDM2, a cancer-driving protein often found at high levels in TNBC and has been linked to faster tumor growth and worse outcomes for patients.